Evidence map›Paper›PMID 30064493›Full record

ArticleBMC cancer2018

Clinical significance of FBXO17 gene expression in high-grade glioma.

Di Du, Jian Yuan, Wencai Ma, Jing Ning, John N Weinstein, Xianrui Yuan, Greg N Fuller, Yuexin Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Di DuDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jian YuanDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Wencai MaDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jing NingDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
John N WeinsteinDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xianrui YuanDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Greg N FullerDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yuexin LiuDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. yliu8@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USCentral South University · CNXiangya Hospital Central South University · CN

Funding

National Cancer Institute Career Development AwardNational Institutes of Health U24 CA143883University of Texas MD Anderson Cancer Center Institutional Research Grant
6 · The paper itself

Abstract

backgroundHigh-grade gliomas (HGGs) exhibit marked heterogeneity in clinical behavior. The purpose of this study was to identify a novel biomarker that predicts patient outcome, which is helpful in HGG patient management.

methodsWe analyzed gene expression profiles of 833 HGG cases, representing the largest patient population ever reported. Using the data set from the Cancer Genome Atlas (TCGA) and random partitioning approach, we performed Cox proportional hazards model analysis to identify novel prognostic mRNAs in HGG. The predictive capability was further assessed via multivariate analysis and validated in 4 additional data sets. The Kaplan-Meier method was used to evaluate survival difference between dichotomic groups of patients. Correlation of gene expression and DNA methylation was evaluated via Student's t-test.

resultsPatients with elevated FBXO17 expression had a significantly shorter overall survival (OS) (P = 0.0011). After adjustment by IDH1 mutation, sex, and patient age, FBXO17 gene expression was significantly associated with OS (HR = 1.29, 95% CI =1.04-1.59, P = 0.018). In addition, FBXO17 expression can significantly distinguish patients by OS not only among patients who received temozolomide chemotherapy (HR 1.35, 95% CI =1.12-1.64, P = 0.002) but also among those who did not (HR = 1.48, 95% CI =1.20-1.82, P < 0.0001). The significant association of FBXO17 gene expression with OS was further validated in four external data sets. We further found that FBXO17 endogenous expression is significantly contributable from its promoter methylation.

conclusionEpigenetically modulated FBXO17 has a potential as a stratification factor for clinical decision-making in HGG.

Indexed as

AdolescentAdultAgedAged, 80 and overBrain NeoplasmsChildCohort StudiesDNA MethylationEpigenesis, GeneticF-Box ProteinsFemaleGliomaHumansMaleMiddle AgedMutationF-Box ProteinsEpigeneticsFBXO17Gene expressionHigh-grade gliomaPrognosis

Identifiers

PMID30064493
PMCPMC6069786
OpenAlexW2885601738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.